Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies.
Allogeneic stem cell transplantation (SCT) is the treatment of choice for many hematological malignancies. Its curative graft-versus-leukemia (GvL) effect is mainly mediated by donor-derived alloreactive T cells. However, if the donor T cells are not selected for their reactivity against leukemic cells, the GvL effect is often associated with graft-versus-host disease (GvHD), a major complication of SCT. Here we summarize our current knowledge on leukemia-associated antigens and discuss strategies to apply minor and major histocompatibility antigens for cellular immunotherapy of hematological malignancies with a low risk of GvHD.
Mutis
Tuna
T
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Goulmy
Els
E
D000951:Antigens, Neoplasm / Q000276:immunology*; D003131:Combined Modality Therapy / Q000379:methods; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive / Q000379:methods
D000951:Antigens, Neoplasm